Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.54 |
| ▸ | JAK3 | P52333 | 9/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.42 |
| ▸ | MTOR | P42345 | 4/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.42 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.42 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.42 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.42 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2161854 | 1.00 | JAK2 (0.54) | JAK2JAK3MAPK1MAPTPIK3CA | |
| SCHEMBL4421973 | 0.87 | JAK2 (0.54) | JAK2JAK3MAPK1MAPTNTRK1 | |
| SCHEMBL2160844 | 0.87 | JAK2 (0.54) | JAK2JAK3MAPK1MAPTNTRK1 | |
| SCHEMBL13573910 | 0.84 | JAK2 (0.60) | JAK2JAK3MAPK1MAPTNTRK1 | |
| SCHEMBL2162064 | 0.82 | JAK2 (0.54) | JAK2JAK3MAPTKCNH2 | |
| SCHEMBL1396445 | 0.82 | JAK2 (0.54) | JAK2JAK3MAPTKCNH2 | |
| SCHEMBL1396515 | 0.82 | JAK2 (0.57) | JAK2JAK3MAPTNTRK1 | |
| SCHEMBL2162010 | 0.82 | JAK2 (0.57) | JAK2JAK3MAPTNTRK1 | |
| SCHEMBL2160983 | 0.81 | JAK2 (0.57) | JAK2JAK3NTRK1 | |
| SCHEMBL4571027 | 0.80 | JAK2 (0.74) | JAK2JAK3MAPTNTRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009150462-A1 | TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | WO | disclosed |